Udwadia Zarir F, Moharil Gautam
Department of Pulmonology, Hinduja Hospital and Research Center, Mumbai, Maharashtra, India.
Lung India. 2014 Oct;31(4):336-41. doi: 10.4103/0970-2113.142101.
There is very limited data on the experience and outcome of multidrug-resistant tuberculosis (MDR-TB) patients treated privately out of the DOTS plus program. Goal of this study is to provide characteristics and treatment outcomes of a prospective cohort of MDR-TB patients managed at a private tertiary referral institute.
A prospective analysis of a cohort of MDR-TB patients treated in a tertiary private hospital, with the back-up of a Level 2 mycobacterial laboratory, which has recently received recognition by the Revised National Tuberculosis Control Program (RNTCP) for second-line drug susceptibility (DST). All patients received an individualized MDR regimen on an ambulatory basis.
Our 68% success rates are respectable and show that given the right laboratory backing, MDR-TB can be managed successfully in selected private practice settings.
关于在直接观察治疗短程化疗强化项目(DOTS plus)之外接受私人治疗的耐多药结核病(MDR-TB)患者的经验和治疗结果的数据非常有限。本研究的目的是提供在一家私立三级转诊机构接受治疗的MDR-TB患者前瞻性队列的特征和治疗结果。
对在一家私立三级医院接受治疗的MDR-TB患者队列进行前瞻性分析,该医院有一家二级分枝杆菌实验室提供支持,该实验室最近已获得修订后的国家结核病控制项目(RNTCP)对二线药物敏感性试验(DST)的认可。所有患者均在门诊接受个体化的MDR治疗方案。
我们68%的成功率是可观的,这表明在有合适的实验室支持的情况下,MDR-TB在选定的私人医疗机构中可以得到成功管理。